thelial cells challenged with bradykinin and ATP account for the biological effect of released EDRF.6 But reports also describe different chemical and biological properties of NO and EDRF7,8; therefore, the extent to which the biological activity of bioassayed EDRF can be explained in different vascular systems by NO needs to be further explored.
Control of Coronary Vascular Tone by
Nitric Oxide Malte Kelm and Jurgen Schrader A specific difference-spectrophotometric method was used to measure nitric oxide (NO) release into the coronary effluent perfusate of isolated, constant-flow-perfused guinea pig hearts. Authentic NO applied into the coronary circulation decreased vascular resistance dose dependently and enhanced coronary release of cyclic GMP (cGMP) fivefold. Increasing oxygen tension in aqueous solutions from 150 to 700 mm Hg decreased NO half-life (5.6 seconds) by 32%. During single passage through the intact coronary system, 86% of the infused NO was converted to nitrite ions. Oxidation of NO was more than 30 times faster within the heart than in aqueous solution. Endogenously formed NO was constantly released into the coronary effluent perfusate at a rate of 161±+11 pmol/min. The NO scavenger oxyhemoglobin and methylene blue increased coronary resistance and decreased cGMP release (basal release, 342+±4 fmol/min), whereas superoxide dismutase reduced coronary resistance. L-Arginine (10`M) slightly decreased coronary perfusion pressure and enhanced release of cGMP. NG-Monomethyl L-arginine (10`M) reduced basal release of NO and cGMP by 26% and 31%, respectively, paralleled by a coronary vasoconstriction. Bradykinin in the physiological range from 5x 10`1 M to 10-7 M dilated coronary resistance vessels, which was paralleled by the release of NO and cGMP. Onset of NO release preceded onset of coronary vasodilation in all cases. Upon stimulation with bradykinin, amounts of endogenously formed NO were within the same range as the dose-response curves for exogenously applied NO both for changes in coronary resistance and cGMP release. Acetylcholine (10`M), ATP (10`M), and serotonin (10-8 M) increased the rate of NO and cGMP release, resulting in coronary vasodilation. Our data suggest the following: 1) NO, the most rapidly acting vasodilator presently known, is metabolized within the heart mainly to nitrite and exhibits a half-life of only 0.1 second; 2) in the unstimulated heart, basal formation of NO may play an important role in setting the resting tone of coronary resistance vessels; 3) the kinetics and quantities of NO formation suggest that NO is causally involved in the bradykinin-induced coronary vasodilation; and 4) amounts of NO formed within the heart stimulated with ATP, acetylcholine, and serotonin are effective for vasodilation. (Circulation Research 1990; 66:1561-1575) Edndothelial cells contribute to the control of local vascular diameter by formation of an endothelium-derived relaxing factor (EDRF)' that was proposed by Furchgott et al and Ignarro et al to be identical with nitric oxide (NO).2,3 Subsequently, different laboratories provided evidence that EDRF has pharmacological and chemical properties identical to NO and that a parallelism exists between the formation of nitrogen oxides and the release of EDRF. 45 Furthermore, it has been shown that the kinetics and the amount of NO released from macrovascular endo-ical identity of the substance(s) involved has not been characterized. Furthermore, no information is available concerning whether the kinetics and amount of NO formed within the heart are adequate to contribute to the control of coronary vascular resistance.
The aim of the present study, therefore, was 1) to characterize the kinetics and vasodilative properties of NO infused into the coronary circulation of isolated guinea pig hearts; 2) to measure the in vitro and in vivo half-life of NO and its metabolites in the intact coronary system; 3) to quantitate basal NO release from the isolated heart using a specific spectrophotometric assay; and 4) to determine whether endogenous NO formation is quantitatively sufficient to account for the coronary vasodilation induced by bradykinin, acetylcholine, ATP, and serotonin.
Materials and Methods Isolated Guinea Pig Hearts
Guinea pigs (280-350 g) were stunned by a blow on the neck. The hearts were quickly excised and perfused according to the Langendorff technique with a medium equilibrated with 100% oxygen at 370 C and containing (in mM) NaCl 140, KCl 4.0, CaCl2 1.84, MgCl2 1.03, NaH2PO4 0.42, glucose 5.0, pyruvate 2.0, HEPES 10.0, and indomethacin 0.01 (pH 7.4). Hearts were electrically paced (285 beats/ min) and perfused at constant flow (10 ml/min) by means of a roller pump. Left ventricular pressure (LVP) and dP/dtmax were continuously measured using a fluid-filled balloon inserted into the left ventricle through the cut mitral valve. Left ventricular diastolic pressure was adjusted to 0 mm Hg. Coronary perfusion pressure (CPP) was monitored by a pressure transducer (Statham, P 23/D, Gould, Cleveland, Ohio) connected by a needle to the aortic cannula. For measurement of the kinetics of coronary vasodilation, a second transducer (same type as above) was incorporated into the aortic cannula and connected to a transducer amplifier (Gould, type 12-4615-52) with a brief response time (<50 msec). All hemodynamic parameters were documented on a Gould 2300 recorder. Hearts were used for further study only when 1) CPP was higher than 55 mm Hg and 2) a bolus injection of adenosine (50 ,l, 50 ,uM) decreased CPP by more than 20 mm Hg.
All compounds were infused into the aortic cannula at a rate of 20-100 ,ul/min (Predicor pump, Infoss AG, Basel, Switzerland) for 2 minutes. Unless otherwise stated, the transit time from site of infusion to the level of aortic valve was 3 seconds. For kinetic measurements, onset of coronary vasodilation was corrected for this transit time. To be as precise as possible, onset (offset) of infusion of compounds to be tested was achieved by inserting (removing) a cannula connected to running infusion pumps into (from) a silicon sealed tube incorporated into the perfusion system. NO standards were infused via a steel cannula placed at the beginning of each exper-iment just above the aortic valve near the origin of the coronary arteries.
Measurement of Nitric Oxide
Isolated guinea pig hearts also were perfused with a medium containing oxyhemoglobin (4 ,uM) . The apex of the heart was placed immediately above the bottom of a water-jacketed chamber so that the proteincontaining coronary effluent perfusate dripped from the heart to the outflow tract of the chamber without forming bubbles. An aliquot (8 ml/min) of the coronary effluent perfusate was sucked away by means of a roller pump and transferred to a flow-through cuvette (Suprasil I, 20-mm light path, type 176, Hellma, Muihlheim, FRG). NO release was continuously quantified by a modification of a previously described difference-spectrophotometric method15 using a flowthrough technique elaborated in our laboratory,6'6 which permitted the determination of precise kinetics of the rate of NO formation. The photometric assay used in this study is based on the conversion of oxyhemoglobin to methemoglobin by NO,17 which is completed in less than 100 msec6 according to the following reaction:
Hb(11)02 + NO>Met(III)Hb + N03-Continuous measurement of the extinction difference between the absorption maximum and the isobestic point of oxyhemoglobin versus methemoglobin (A, 401 nm, A2 411 nm) with a double-beam doublewavelength spectrophotometer (Hitachi model 557, Perkin-Elmer, Ueberlingen, FRG) permitted continuous assay of the NO released. NO concentrations were calculated from the extinction coefficient, which was determined under the conditions used in this study to be 38 mM-1 cm-'. Previously described specificity of the assay for detection of NO under in vitro conditions15"18 and in biological systems616 was extended by the following control experiments: nitrite and nitrate, both metabolites of NO in aqueous solution, infused into the perfusion medium did not interfere with the difference-spectrum in a concentration up to 10`4 M. The molar differenceextinction coefficient (determined from a differencespectrum of oxyhemoglobin versus increasing amounts of methemoglobin elicited by NO) was identical in the perfusion medium bypassing the heart and in the coronary effluent perfusate. NO concentrations determined by difference-spectrophotometry were validated by infusion of aqueous NO standards. The concentration of oxyhemoglobin applied refers to the concentration of the hemoprotein, which is 25% of the respective value for hemoglobin. A concentration of 4 ,M oxyhemoglobin in the perfusion medium was chosen because at this concentration a linear relation exists between the amount of NO and the extinction difference in the difference-spectrum. In addition, the perfusion medium became only slightly turbid at 4 gM oxyhemoglobin, yielding a good signal-to-noise ratio in the difference-spectrum obtained with the photomultiplier.
The Po2 in the perfusion medium equilibrated with 100% oxygen was greater than 700 mm Hg. The respective value in the coronary effluent perfusate ranged between 200 and 291 mm Hg (n=6; pHM 73 blood gas analyzer, Radiometer, Copenhagen, Denmark). The extinction coefficient for the NO measurement was the same in perfusion medium equilibrated with room air or saturated with 100% oxygen. The pH in the coronary effluent perfusate was 7.2-7.31 (n =4), and in this range the difference-spectrum was not significantly altered. Because the NO assay is known to be temperature dependent, all tubes for the perfusion medium, the effluent perfusate, and the flow-through cell in the spectrophotometer were maintained at 370 C. For measurements of the kinetics of NO release from isolated hearts, the passage time of medium dripping off the heart to the spectrophotometer (9 seconds) was determined by infusion of methemoglobin standards. Data concerning kinetics of NO release were corrected for this interval. All compounds used for challenging NO release were controlled for interference with the assay. Nitrite and nitrate, both products of NO oxidation, did not interfere with the assay in a concentration up to 100 ,uM under the conditions used in this study (n=4).
Preparation of oxyhemoglobin was carried out according to the protocol described in detail previously. 15 Briefly, bovine hemoglobin was dissolved in water (pH 7), equilibrated with oxygen, reduced with a molar excess of sodium dithionite, and purified by gel chromatography. Content and purity were controlled spectrophotometrically at 415 nm.19 Methemoglobin was prepared by treating bovine hemoglobin with a 10-fold molar excess of potassium ferricyanide, followed by gel filtration. Purity was controlled spectrophotometrically at 630 nm after addition of 20% K3Fe (CN)6 and 5% KCN.20 Nitric Oxide Solutions and High-Performance
Liquid Chromatography
Standards of aqueous NO solutions were prepared according to the following procedure: NO gas (Schuchardt, Miinchen, FRG) was bubbled for approximately 25 minutes through three gas-tight vials connected in-line. The first vial contained 5% (wt/vol) pyrogallol in a potassium hydroxide-saturated solution to scavenge traces of oxygen; the second contained 10% (wt/vol) potassium hydroxide to scavenge higher nitrogen oxides; and the third contained highperformance liquid chromatography (HPLC)-grade water (LiChrosolv, Merck, Darmstadt, FRG). Before NO was added, the system was equilibrated for 45 minutes with argon. The concentration of the NO stock solution (third vial) was 2-3 mM. To prepare NO solutions of different concentrations, aliquots of this solution were injected with a gas-tight syringe into other vials containing argon-degassed water. All vials were stored under argon atmosphere. NO solution used for intracoronary infusion was kept in glass syringes connected to the infusion cannula by HPLC steel tubing. With these precautions, NO concentration remained stable for up to three hours.
The concentration of NO in stock solutions was determined by conversion of NO to nitrite ions using HPLC. Separation of nitrite from nitrate ions was carried out using a 7-gm (i.d.) LiChrosorb NH2 column (Merck) eluting with 1% (wt/vol) KH2PO4 (pH 3.2) at 1.9 ml/min (250 C). 15 Detection was set at 208 nm. NO is oxidized in aqueous solutions (equilibrated with room air) exclusively to nitrite, according to the following reaction mechanism21:
Therefore, measurement of nitrite ions allowed for precise determination of the respective NO concentration. The amount of nitrate was consistently less than 3%.
Bioassay
An isolated perfused, endothelium-denuded, precontracted segment of rat aorta served as a stable bioassay for NO. 22 Aortas precontracted with norepinephrine (0.2 ,uM) were perfused at constant flow with 2 ml/min and a pressure of 60 cm H20. Changes in vessel diameter were recorded by a pair of piezoelectrical crystals (4 MHz). Endothelium was removed by treatment with deoxycholic acid (0.75%; 15 seconds). From the effluent perfusate released by the heart, 2 ml/min was transferred to the isolated rat aorta by means of a roller pump. Transit time from the apex of the heart to the rat aorta was 3 seconds.
Determination of Nitric Oxide Half-life
In vitro NO half-life was measured at different oxygen partial pressures of the perfusion medium. Perfusate was equilibrated either with room air (P02, 150 mm Hg; range, 135-160 mm Hg) or saturated with 100% oxygen in water-saturated atmosphere (Po2, 700 mm Hg; range, 690-720 mm Hg). Aqueous NO standards were infused into a tubing system perfused with the above-mentioned medium at 2 ml/min. Sites of NO infusion were separated from the site of oxyhemoglobin infusion (4 ,uM) by a transit time ranging from 0 to 12.7 seconds. At time zero, NO and oxyhemoglobin were infused at the same site, so that all infused NO was scavenged by oxyhemoglobin because of the brief response time of the spectrophotometric assay. The decreasing extinction with increasing transit time is expressed as percent of maximal extinction difference at time zero.
The NO half-life under in vivo conditions was determined by two independent methods. NO standards were infused into the coronary circulation of isolated guinea pig hearts, and the effluent perfusate was assayed for NO using either chemical detection by difference-spectrophotometry or a bioassay. In the case of the spectrophotometric assay, 4uAM oxyhe-moglobin was added to the effluent perfusate, which was immediately transferred for spectrophotometric measurement. In the case of the bioassay, an aliquot of the coronary effluent perfusate (2 ml/min) dripping from the heart placed in a water-jacketed funnel sealed with silicon rubber was sucked away by a roller pump (Reglo MS-4, Ismatec, Switzerland) and transferred by silicon tubes (0.57-mm diameter) to an isolated, precontracted, endothelium-denuded segment of rat aorta (transit time from the heart to the aorta, 3 seconds). Transit time through the heart was determined by infusion of Evans blue (1 mg/l) to approximate 1 second (0.86+0.01; n=3), which is in accordance with previously reported results.9 The amount of nitrite ions in the coronary effluent perfusate was measured in parallel by HPLC.
The in vivo NO half-life in the intact coronary system was calculated from transit time, given flow rate, and from the ratio of infused NO standards and the measured NO concentrations in the coronary effluent perfusate, assuming pseudo-first-order kinetics of elimination.
Measurement of Cyclic GMP
Coronary effluent perfusate (10 ml) was passed over two Sep-Pak C18 cartridges (Waters, Eschbaum, FRG) connected in-line that had been treated with 2 ml propanol 40% (vol/vol), followed by 2 ml distilled water and by 2 ml KH2PO4 (0.01 M). Adsorbed cyclic GMP (cGMP) was eluted with 2 ml propanol 40% (vol/vol) and evaporated to dryness with a Vortex evaporator (Buchler, Fort Lee, New Jersey). The residue was dissolved in 110 ,l distilled water for determination of cGMP by radioimmunoassay. Capacity and reproducibility of the separation procedure was tested with 50 1,l 3H-cGMP (427 fmol cGMP; specific activity, 20 nCi/pmol) dissolved in 10 ml perfusate (n=4), yielding 82-86% recovery of cGMP.
Data of cGMP release were not corrected for loss occurring during sample purification.
Cyclic GMP was determined with a commercially available radioimmunoassay (Amersham, Braunschweig, FRG). The antiserum and (8-3H)guanosine 3'Y:5'-cyclic phosphate were diluted twofold, resulting in a linear calibration curve from 0.1 to 3 pmol cGMP per tube. Radioactivity was measured by liquid-scintillation spectrometry (PW 4700, Philips Eindhoven, The Netherlands) after addition of 10 ml scintillation fluid (Atomlight, NEN, Boston, Massachusetts). All compounds used to influence cGMP release of the heart (bradykinin, oxyhemoglobin, methemoglobin, methylene blue, superoxide dismutase, and isoproterenol) did not interfere with the radioimmunoassay or influence sample purification.
Chemicals and Statistical Analysis
Analytical-grade substances were obtained from the following supply houses: bradykinin, indomethacin, methylene blue, pyrogallol, (±+)-isoproterenol, serotonin, L-arginine hydrochloride, and bovine hemoglobin from Sigma (Munich, FRG); adenosine and ATP from Boehringer (Mannheim, FRG); superoxide dismutase (EC 1.15.1.1) from Serva Feinbiochemica (Heidelberg, FRG); norepinephrine (Arterenol) from Hoechst (Frankfurt, FRG); acetylcholine from Dispersa (Munich, FRG); sodium nitroprusside from Schwarz (Monheim, FRG); NG-monomethyl L-arginine citrate (L-NMMA) from Ultra Fine Chemicals (Manchester, UK); and sodium dithionite and potassium ferricyanide from Merck (Darmstadt, FRG).
Isolated guinea pig hearts were tested for even distribution regarding basal hemodynamic parameters (n=119) using Gaussian function. To compare control values with those obtained during the different interventions, Student's two-tailed t test for either paired or unpaired data was used. Differences were considered to be significant at p<0.05. Values are given as mean±+SEM unless otherwise stated; n indicates number of isolated guinea pig hearts used to study the intervention indicated.
Results

Effects of Nitric Oxide on Hemodynamic Parameters
Basal hemodynamic parameters of isolated guinea pig hearts (n=119) perfused at a constant flow of 10 ml/min were LVP, 50+1 mm Hg; dP/dtma, 662±13 mm Hg/sec; and CPP, 70+1 mm Hg. Infusion of NO into the coronary arteries dilated coronary resistance vessels dose dependently; threshold concentration was 1 nM and EC50 was 7 nM (Figure 1 ). Repetitive infusion (five times) of 100 nM NO for 2 minutes elicited no tachyphylactic response (n=4). LVP and dP/dtm. were not significantly influenced by NO.
Infusion of adenosine (5 ,uM) on top of a maximally effective dose of NO (0.5-1 ,uM) further decreased CPP by 11±4% (n=3). Sodium nitroprusside applied at a maximally effective dose (100 ,uM) decreased CPP by 39±2 mm Hg (n=3), and this effect was not enhanced by simultaneous infusion of adenosine (10-5 M), ATP (10-5 M), or bradykinin (10-7 M) (n=3 for each substance). Infusion of NO2and NO3-(1 ,uM), both products of NO degradation in aqueous solutions, did not influence CPP (n=3).
Data on the kinetics of NO-induced coronary vasodilation as compared with those of bradykinin, adenosine, and ATP are summarized in Table 1 . Among all substances tested, NO acted the most quickly, reaching maximal vasodilation after an interval that was about 50% shorter than that required for bradykinin, adenosine, and ATP.
Metabolism and Nitric Oxide Half-life
The in vitro NO half-life at 370 C was 5.6 seconds when the perfusion medium was equilibrated with room air (Po2, 150 mm Hg) and 3.8 seconds when the medium was equilibrated with 100% oxygen (Po2, 700 mm Hg). In both cases, elimination of NO followed pseudo-first-order kinetics ( The amount of NO recovered in the coronary effluent perfusate after its application into the coronary arteries (in vivo NO half-life) was measured by bioassay and by the spectrophotometric assay for NO.
In the case of the bioassay, the isolated guinea pig heart and an isolated segment of rat aorta were perfused in series at constant flow. Calibration of the bioassay revealed that the threshold concentration for NO-induced vasodilation was 1 nM and EC50 was 5 nM (Figure 3 , curve I), which is almost identical to the sensitivity of coronary resistance vessels for infused NO (Figure 1 ). When NO was infused into the coronary circulation, the rat aorta segment dilated only when the NO concentration exceeded 10`' M (Figure 3 , curve III). To calculate the half-life of NO, additional knowledge of the transit time of medium passing through the heart and the transit time of medium leaving the heart until reaching the bioassay is required. Transit time through the heart, determined with Evans blue (1 mg/l), was less than 1 second (n=3). The coronary sinus effluent took 3 seconds to reach the bioassay at the given flow rate. Correction for subsequent loss of NO shifts the dose-response curve for NO to the right (Figure 3 , curve II, shift A); thus, the difference between curves II and III in Figure 3 (shift B) is exclusively due to NO degradation during passage through the heart. Comparison of the data given in Figure 3 reveals that (6) Adenosine (10-5 M) 2.1±0.2 (5) 73±9 (4) 47±5 (5) ATP (10-7 M) 3 .2±0.1 (5) 62±4 (5) 44±9 (4) Values are expressed as mean±SEM. Latent period, interval between start of infusion and start of response; maximum, interval between start of response and maximal vasodilation; half recovery, interval between stop of infusion (2 min after start of infusion) and half recovery from maximal response. Data are corrected for transit time (see "Materials and Methods"). Concentrations of substances applied were chosen to elicit a maximal vasodilatory response (nitric oxide, -43±3; bradykinin, -63±1; adenosine, -56±5; ATP, -53±4 percent coronary perfusion pressure). Number in parentheses, number of isolated guinea pig hearts tested by the respective substance. more than 98% of infused NO became inactivated during a single passage through the heart. Assuming first-order kinetics of NO elimination during coronary passage, half-life was calculated to be 130 msec.
To verify the data on the in vivo NO half-life obtained in the bioassay, experiments were carried out in which the recovery of intracoronarily infused NO was determined in four hearts using the spectrophotometric NO assay. When NO was applied in the concentration range from 2x10`6 M to 7x10-5 M, less than 1% of the infused NO was recovered in the effluent perfusate ( Figure 4 ). Again assuming firstorder kinetics of NO elimination, half-life was calculated to be 111 msec (K=6.25+0.145 sec-1, n=1 1). In addition to NO, the concentration of released NO2--the major product of NO metabolism in the coronary vascular system -was measured by HPLC. FIGURE 3 . Measurement of NO degradation during single passage through heart by bioassay. Isolated guinea pig hearts and isolated segments of rat aorta perfused in series. Amount of exogenously applied NO recovered in coronary effluent perfusate measured by degree of relaxation in bioassay. Curve I: Dose-response curve ofthe vasodilative effect ofNO, applied directly into lumen of rat aorta (true sensitivity of the bioassay). Curve II: Dose-response curve corrected for loss of NO during passage through the tubing system connecting the heart and rat aorta (shift A; for details see "Materials and Methods"). Curve III: Measured degree of relaxation in rat aorta when NO was infused into heart in indicated concentration range. Coronary flow was 10 ml/min. Transit time for perfusion medium leaving heart to rat aorta, 3 seconds. In vivo NO half-life in coronary vascular system calculated from transit time through heart (1 second) and ratio of infused NO to amount of bioassayed NO (shift B). more than 86% was converted to NO2and was released as such into the coronary effluent perfusate ( Figure 4 ). The remaining 14% of the infused NO could not be identified.
Release of Endogenously Formed Nitric Oxide
In 21 hearts, the basal release of NO into the coronary effluent perfusate was determined to be 161+±11 pmol/min. Perfusion of heart with 4 ,uM oxyhemoglobin, which is required to trap NO formed within the heart, significantly decreased coronary perfusion pressure by 4.5+0.4% (n=26).
Data on the effect of increasing concentration of oxyhemoglobin and methemoglobin on the basal coronary vascular tone are summarized in Figure 5 . Oxyhemoglobin dose-dependently increased coronary perfusion pressure of volume-constant perfused hearts, whereas methemoglobin in the same concentration range was ineffective except at the highest concentration studied ( Figure 5 , Table 2 ). Perfusion with oxyhemoglobin did not alter LVP or dP/dtm,,.
Furthermore, bolus injection of adenosine (50 ,ul, 50 ,uM) caused the same extent of coronary vasodilation in the presence or absence of 4 ,uM oxyhemoglobin (IACPP, -23 +2 mm Hg, n =8).
The results of a separate series of experiments confirm that there is a basal release of NO from the isolated heart. Superoxide dismutase, which prolongs 1.5 ±0.4% (n=3). In the presence of 4 ,uM oxyhemoglobin, this effect was abolished (n=4). Basal release of NO was not measurably affected by L-arginine (n=3). L-NMM1A (10-4 M), a potent inhibitor of L-arginine-derived NO synthesis,23'24 significantly increased CPP by 7±1.2% (n=4), whereas rate of NO formation was reduced by 26±3% (n =3). L-Arginine and L-NMMA did not affect LVP or dP/dtmax. The hemodynamic effects of bradykinin are summarized in Table 3 . Bradykinin dose-dependently reduced CPP without significant changes in contractile parameters. Oxyhemoglobin significantly decreased the bradykinin-induced coronary vasodilation (Table  3 ). In the presence of 4 ,M oxyhemoglobin, the EC50 value for bradykinin increased from 3 x 10-10 M for the control to 10-M.
Stimulation of isolated hearts with bradykinin in the physiological concentration range of 5 x 10-10-10`M dose-dependently enhanced the rate of NO formation ( Figure 6 ). Bradykinin at the maximal effective dose of 10-7 M increased NO release threefold above basal value. NO release started 1±0.4 seconds (n=8) after start of stimulation with brady- of NO release and vasodilation (1.4 seconds) corresponds to the latent period of the coronary vascular smooth muscle to exogenously applied NO (Table 1) .
In a separate experimental series, an attempt was made to determine endogenously formed NO with the bioassay. The isolated heart was perfused in series with an isolated segment of rat aorta as described above. In two experiments, maximal effective doses of bradykinin (100 nM) did not cause relaxation of the endothelium-denuded rat aorta.
Repetitive stimulation (five times) of isolated hearts (n=4) with 100 nM bradykinin for 2 minutes did not elicit tachyphylaxis of NO release or attenuation of coronary vasodilation. Similarly, when hearts (n=2) were stimulated over 30 minutes with 100 nM bradykinin, NO release was enhanced to a new steady state, reaching the same level as described above. Oxyhemoglobin (HbO2, 4 ,uM) increased basal coronary perfusion pressure (CPP) in isolated, electrically paced and constant-flow-perfused guinea pig hearts from 69±3 to 73±3 mm Hg. Bradykinin-induced changes in CPP are expressed as percent of the respective control. Asterisks indicate significant differences in the presence of oxyhemoglobin (HhO2) evaluated by two-tailed Student's t test for unpaired data. ND, not determined; n, 7-11. Increasing the concentration of oxyhemoglobin from 4 to 100 ,uM further inhibited the bradykinininduced coronary vasodilation (Figure 7) . At 100 ,uM oxyhemoglobin, the coronary vasodilative effect of 1 nM bradykinin was decreased by more than 80%. This inhibitory effect was less pronounced at 100 nM bradykinin. Again, 100 ,uM methemoglobin did not alter the bradykinin-induced coronary vasodilation, suggesting that the NO scavenging effect of oxyhemoglobin was specific. Acetylcholine (10`M) and ATP (10`M) consistently enhanced basal rate of NO release, which was paralleled by coronary vasodilation ( Table 4 ). The enhancement of NO release with both stimuli was considerably lower than that obtained upon stimula-tion with bradykinin. Because the enhancement of NO release obtained in the difference-spectrum was only small, no attempt was made to determine the kinetics for the onset of NO release. It should be mentioned, however, that after cessation of ATP infusion, changes in NO release and coronary perfusion pressure reached basal levels within 1 minute, whereas acetylcholine-induced changes in both parameters were not reversed before 5 minutes. Acetylcholine-induced coronary vasodilation was considerably reduced by 4 ,uM oxyhemoglobin, whereas changes in CPP elicited by ATP were not affected. Serotonin at 10`8 M enhanced the rate of NO formation, paralleled by a significant reduction of CPP. In the presence of 4 ,uM oxyhemoglobin, however, serotonin caused a coronary vasoconstriction (Table 4 ). Serotonin, acetylcholine, and ATP in the indicated concentrations did not significantly affect LVP or dP/dtmx. When hearts were stimulated with adenosine (10-5 M), no additional NO release was detectable (n=4). Coronary Release of Cyclic GMP Basal release of cGMP into the coronary effluent perfusate was measured in 24 hearts to be 342±4 fmol/min. Perfusion of the hearts with a medium containing 4 gm oxyhemoglobin significantly decreased cGMP release by 162±21 fmol/min (n=11, p<0.05). Methemoglobin (4 ,uM) did not significantly influence the release of cGMP (n=3), whereas methylene blue (30 ,M) decreased cGMP release by 141 ± 17 fmol/min (n =4,p<0.05). L-Arginine (10-5 M) enhanced basal release of cGMP by 79±27 fmol/min (n=3, not significant). In the presence of 4,M oxyhemoglobin, this effect was blunted. L-NMMA (10-4 M) significantly reduced basal release of cGMP by 108±17 fmol/min (n=4), and isoproterenol (10-8 M) did not alter cGMP release (n=4).
Exogenously applied NO increased coronary venous release of cGMP dose dependently (Figure 8 ). Maximal release of cGMP at 3 x 10`M NO was fivefold above basal release. Threshold concentration for the NO-induced cGMP release was 1 nM, which was the same for the NO-induced changes in CPP.
Bradykinin increased cGMP release into the coronary effluent perfusate (Figure 9 ). Similar to find- Oxyhemoglobin (HbO2, 4 ,uM) increased basal coronary perfusion pressure (CPP) in isolated, electrically paced and constant-flow-perfused guinea pig hearts from 60.7±2.9 to 62.3±3.1 mm Hg; changes in CPP are expressed as percent of the respective control. n, 3-4 (each group). ings with NO, the maximal response with bradykinin (10`7 M) was fivefold above basal cGMP release. The concentrations of bradykinin required to elicit this effect were similar to those necessary to decrease CPP. Again, 4 4M oxyhemoglobin shifted the doseresponse curve of the bradykinin-induced cGMP release to the right and significantly decreased maximal response (Figure 9 ). Figure 10 shows the comparison of the effects of exogenously applied and endogenously formed NO on changes in CPP and cGMP release. Both for coronary vasodilation and cGMP release, the doseresponse curves of endogenously formed and exogenously applied NO were within the same range. Serotonin (10-8 M, not significant), acetylcholine 
4).
As was the case with bradykinin, the relation of coronary vasodilation and the NO concentrations measured in the coronary effluent perfusate from hearts stimulated with acetylcholine (10.2 nM NO; IACPP, -31%) and serotonin (2.3 nM NO; ACPP, -6%) was within the same range of the doseresponse curve for exogenously applied NO (see Figure 1 ). The ATP-induced coronary vasodilation, however, was much more pronounced than would be predicted from the measured NO concentration (5.3 nM NO; ACPP, -44%).
Discussion
The present study provides the first evidence that 1) the quantities of NO released into the coronary circulation are sufficient to play an important role in the control of basal coronary vascular tone; 2) the half-life of NO in the heart is only 0.1 second, which is more than 30 times shorter than values determined under in vitro conditions; 3) the kinetics and quantities of NO liberated by bradykinin are sufficient to account for the bradykinin-induced coronary vasodilation; and 4) the enhanced rate of NO formation elicited by acetylcholine and serotonin is sufficient to mediate observed coronary vasodilation, whereas in the case of ATP, additional mechanisms aside from NO appear to be involved.
Effects of Nitric Oxide on Hemodynamic Parameters
When infused into the coronary circulation, NO constitutes a very fast acting, potent, and extremely labile coronary vasodilator. The threshold concentration and EC50 value of NO in the isolated heart were 1 and 7 nM, respectively, which indicates that the sensitivity of the coronary resistance vessels is almost identical to that of vascular smooth muscle in the isolated rat aorta as previously determined.6 Onset of coronary vasodilation occurred 1.4 seconds after the start of NO infusion, and this interval is the shortest compared with all other tested coronary vasodilators such as ATP, adenosine, and bradykinin. Most likely, the rapid onset of NO action can be explained by the fact that NO is a second messenger acting directly on vascular smooth muscle guanylate cyclase without requiring any receptor activation.
Repetitive stimulation with NO did not cause tachyphylaxis of the coronary flow response, suggesting that the sensitivity of the smooth muscle guanylate cyclase system mediating the NO-induced vasodilation is unaltered. Therefore, the well-known phenomenon of "nitrate tolerance" observed upon repetitive application of organic nitrates, presumably acting through NO,15 may be due to impaired metabolism of organic nitrates. 25 In contrast to adenosine, NO concentrations as high as 1 ,uM elicited only submaximal coronary vasodilation. Two explanations appear reasonable. First, the sensitivity of the vascular smooth muscle for various vasodilators may be different along the coronary artery system.26 Second, because of the extremely rapid degradation of NO, the effective NO Figure 1 ); solid line, NO released into the coronary effluent perfusate at different concentrations of bradykinin (BK) is plotted against the respective changes in CPP (data are from Figure 6 and Table 3 ). Changes in CPP given in percent concentration at the site of coronary resistance vessels most likely is considerably reduced. In support of the latter interpretation is our observation that sodium nitroprusside, which induces vessel dilation by the local liberation of NO, elicited maximal coronary vasodilation that could not be further enhanced by adenosine, ATP, and bradykinin. It has been shown by several laboratories that NO-induced vasodilation is mediated by increased intracellular levels of cGMP in smooth muscle cells (for review, see Ignarro and Kadowitz27 and Rapoport and Murad28). Consistent with this view is our finding that NO-induced coronary vasodilation was paralleled by respective changes in the release of cGMP into the coronary effluent perfusate. To our knowledge, this is the first report that links cGMP release into the coronary effluent perfusate with coronary vascular tone. Although released cGMP is presumably derived from the coronary vascular cells, the mechanism of its release remains to be investigated.
Metabolism and Nitric Oxide Half-life
The present study confirms previously reported results21 that under in vitro conditions (aqueous solutions), NO is converted exclusively to nitrite. We now demonstrate that after a single passage of NO through the intact coronary system of the isolated heart, more than 86% of the infused NO is metabolized to nitrite (Figure 4 ). This finding does not support the view that in aqueous solution NO is first oxidized to NO2 and then hydrolized to yield equimolar concentrations of nitrite and nitrate.4,13 Data reported in the literature concerning the degradation of NO under in vivo conditions are inconsistent. This is most probably due to the different cellular systems studied and assay conditions applied. Cultured macrophages have been shown to synthesize nitrite and nitrate from Larginine-derived NO in a ratio of 3:2, whereas in the cytosolic fraction the ratio was 1: 2.2.29 It has also been reported that in mice and rabbits, 70% of the nitrite is converted to nitrate when intravenously administered.30 Most likely, this conversion occurs predominantly within erythrocytes, in which conversion of nitrite to nitrate in excess of nucleophilic agents has been described. 31 Thus, although the pathway of NO in the saline-perfused heart is predominantly nitrite, routes of NO oxidation under in situ conditions may be different.
A major result of the present study is the finding that the half-life of NO infused into the coronary arteries is extremely short. During a single passage through the heart, more than 98% of infused NO is metabolized, and the NO half-life determined by two independent methods (bioassay and differencespectrophotometry) was as short as 0.1 second (Figures 3 and 4) . Thus, in the intact coronary circulation, NO degradation is more than 30-fold faster than when measured under in vitro conditions. This most likely explains the fact that although NOreleasing concentrations of bradykinin were applied, no EDRF/NO could be detected in the coronary effluent perfusate using the isolated rat aorta as a bioassay. The short in vivo NO half-life may have several important physiological consequences. The action of NO formed by endothelial cells is most likely confined to the immediate vicinity of its site of production. Unless the dilative effect is not propagated by electrical phenomena,32-34 NO formation -60-
may be a very specific means to influence coronary vascular tone in localized areas. Another more general consequence of a short half-life is the possibility that the effective NO concentration may be not only controlled by its rate of formation but also by its rate of degradation, because NO half-life depends highly on Po2 (Figure 2) .
Aside from molecular oxygen, superoxide anions were suggested to be involved in the rapid breakdown of EDRF. 35 In our experiments, however, perfusion of isolated hearts with superoxide dismutase only slightly increased vascular tone, suggesting that the formation of superoxide anions within the heart is of only minor importance. A superoxide dismutase localized on the extracellular surface of endothelial cells may have contributed to the rapid inactivation of superoxide anions within the coronary circulation.36 Finally, data obtained with the electron spin resonance technique suggest that hydroxyl free radicals may have been released by isolated hearts predominantly during aerobic reperfusion.37 In this context, it seems of interest to note that hydroxyl radicals and NO may react to form nitrite (. OH+NO. ->N02 +H+) and thus account not only for the measured oxidation of NO to nitrite but also for the short in vivo NO half-life.
Basal Release of Nitric Oxide
Because of the instability of NO in aqueous solutions, NO measurement is difficult and has led to the development of several methods aimed to quantitate NO formation in biological samples. These methods include 1) measuring NO as nitrite, which is reduced in a reaction vial back to NO and detected by chemiluminescence4 or is followed by diazotization of sulfanilic acid and spectrophotometric determination according to the Griess reaction38,39; 2) scanning spectrophotometry using peak shift of deoxyhemoglobin induced by binding of NO3; and 3) using isotope precursors and detecting the 15NO isotope by mass spectrometry. 40 A major difficulty when measuring NO indirectly by nitrite in more intact biological preparations is the finding that nitrite and nitrate in body fluids and presumably in the cells are normally within the micromolar range. 41 Changes in NO formation that usually occur in the nanomolar range therefore may remain undetected. In contrast, the method used in the present study has the advantage of directly scavenging the free NO radical. Many substances are known to oxidize hemoglobin by different mechanisms, such as interaction with the bound oxygen, direct oxidation of the central iron, or biochemical transformation of the hemoglobin (for review, see Bunn and Forget42). The difference-spectrophotometric assay used in this study is based on a conversion of oxyhemoglobin to methemoglobin by NO via a cooxidation. This process is completed in less than 100 msec as previously determined by our laboratory using a spectrophotometric stop-flow technique.6 To our knowledge, no other substance with such a high affinity to oxyhemoglobin as NO has been described in the literature so far. Recently, the nature of the iron-oxygen bond in the oxyhemoglobin molecule has been described to appear as a superoxide anion attached to the central ferrous atom of the hemoprotein (Hb3+O2-). 31, 42 This may explain the facilitated and extremely rapid cooxidation of oxyhemoglobin and NO. The measured velocity of this reaction is an important prerequisite to derive the kinetics of the rate of NO formation, because the degradation of NO in the intact coronary circulation occurs extremely rapidly and the passage time through the heart was less than 1 second under the conditions used in this study. The reaction kinetics of all other substances capable of oxidizing oxyhemoglobin, for example, nitrite, which had been reported in the literature so far, are in the range of minutes42-44 instead of milliseconds as in our detection system. This is in accordance with our finding that nitrite and nitrate even at a concentration of 100 ,uM did not alter the difference-spectrum. Even if the heart would form a so far unknown substance capable of altering the conformation of oxyhemoglobin in less than 100 msec, this must not only deoxygenate oxyhemoglobin but also simultaneously or subsequently oxidize hemoglobin to methemoglobin, otherwise no signal would be detectable in the difference-spectrum at 401 and 411 nm. This, however, seems very unlikely, because the molar extinctions coefficient determined by recording a difference-spectrum under static conditions, instead of the flow-through technique, was identical in an aliquot of the perfusion medium bypassing the heart and of the coronary effluent perfusate. Therefore, even under basal conditions, no other substance than NO was tonically released from the heart, which specifically altered the difference-spectrum. Collectively, these data indicate that the differencespectrophotometric assay used in this study specifically detected the release of the free NO radical and in addition permitted for the first time the determination of the kinetics of NO formation, which is an important prerequisite to evaluating its role in the regulation of coronary vessel tone.
Endothelium-derived NO reaches the vascular smooth muscle either by diffusion across cellular membranes or through the numerous gap junctions existing between endothelial and smooth muscle cells. 45 Clearly, oxyhemoglobin is confined to the extracellular space and can only scavenge NO present in the interstitium and in the vessel lumen.
Perfusion of the heart with an oxyhemoglobincontaining medium can therefore be expected to scavenge all the luminally released NO. The extent to which abluminally released NO is detected by this system critically depends on the concentration of oxyhemoglobin in the interstitial fluid space. There are several reasons to assume that the velocity of exchange of macromolecules such as oxyhemoglobin across the endothelial barrier of the heart is quite rapid. Wienen and Kammermeier46 demonstrated that after 3 minutes, more than 50% of infused albumin, which is similar in molecular mass to hemo-globin, was detected in the interstitial transudate of the isolated perfused rat heart. Consistent with this observation is our finding that within 30 seconds after the start of an oxyhemoglobin infusion, CPP began to rise, reaching its maximum after 2 minutes.
Isolated guinea pig hearts released NO into the coronary effluent perfusate under basal conditions at a rate of 161 pmol/min, resulting in the formation of cGMP in the unstimulated heart. This extends previously reported data on basal release of EDRF in conduit arteries47 and in the isolated rabbit heart.48
Scavenging released NO with oxyhemoglobin not only significantly increased coronary vascular resistance but also decreased coronary venous release of cGMP. Our findings obtained with methylene blue and superoxide dismutase are consistent with the interpretation that basal formation of NO is quantitatively sufficient to be a major factor in setting the resting tone of coronary resistance vessels. Methylene blue, an inhibitor of NO-sensitive soluble guanylate cyclase,49-51 increased CPP. Because oxyhemoglobin and methylene blue act through different mechanisms, simultaneous infusion of both substances was additive in increasing coronary resistance. Furthermore, oxyhemoglobin reversed the coronary vasodilation induced by superoxide dismutase. Similarly, oxyhemoglobin prevented the effects of superoxide dismutase on EDRF/NO released from endothelial cells. 6 Obviously, the NO scavenging ability of oxyhemoglobin is much faster than the dismutation of superoxide anions by superoxide dismutase.
Recently, L-arginine has been postulated as a precursor of NO in macrophages, cultured endothelial cells, isolated vessels, and intact animals.29394052 In the present study, L-arginine slightly but significantly decreased CPP, whereas L-NMMA, a potent and selective inhibitor of arginine-derived synthesis,2324 significantly decreased basal release of NO and cGMP, resulting in coronary vasoconstriction. This finding is in accordance with previously described results24,52 that L-arginine, the substrate for NO synthesis, is presumably abundant within cells, so that additional infusion of L-arginine elicited only small effects, whereas the inhibitor induced pronounced effects. These data are therefore consistent with the view that NO formed within the unstimulated heart may be derived from L-arginine.
The present study provides strong evidence that, aside from oxygen, carbon dioxide, potassium, and possibly adenosine (for review, see Feigl9), basal formation of NO is an important factor involved in the local modulation of resting tone of coronary resistance vessels. There are good reasons to assume that the NO-mediated control is not restricted to the saline-perfused isolated heart: Increasing plasma hemoglobin in blood-perfused rabbit hearts, while keeping total hemoglobin and arterial oxygen content constant, exerted a pronounced coronary vasoconstrictory effect.53
Bradykinin-Induced Nitric Oxide Release
Bradykinin is known to influence many important parameters of endothelial cell metabolism and function. It raises intracellular calcium,33 causes a transient hyperpolarization,54 and evokes the release of EDRF55 and prostaglandins (for review, see Regoli and Barabe56) . Although the in vivo half-life of bradykinin is rather short (<0.5 minutes) and most of the bradykinin is extracted during its passage through the lung,57 it must be considered a potent coronary vasodilator because the sensitivity of coronary arteries to bradykinin is considerably higher compared with other vascular beds. 56 In the present study, the bradykinin-induced changes in coronary resistance were paralleled by respective changes in the release of NO and cGMP into the coronary effluent perfusate. Several criteria must be fulfilled for postulating NO to be responsible for the bradykinin-induced coronary vasodilation, such as the demonstration that 1) the kinetics of NO release must precede coronary vasodilation, and 2) the amount of released NO must be quantitatively sufficient to induce coronary vasodilation.
Onset of bradykinin-induced NO release occurred 1 second after start of stimulation, whereas onset of coronary vasodilation was after 2.4 seconds ( Table 1) . The interval between start of NO release and vasodilation exactly corresponds to the response time of coronary vascular smooth muscle, determined to be 1.4 seconds.
The dose-dependent enhancement of the basal release of NO and cGMP induced by bradykinin was within the same range as the dose-response curve for exogenously applied NO (see Figure 10 ). This finding clearly demonstrates that vasodilative, effective amounts of NO were formed within the heart and suggests that the bradykinin-induced coronary vasodilation is mediated by NO via activation of guanylate cyclase.
Oxyhemoglobin inhibited the bradykinin-induced coronary vasodilation. Methemoglobin was ineffective, again demonstrating the specificity of the NOscavenging effect of oxyhemoglobin. The magnitude of the inhibitory effect, however, was strongly dependent on the intraluminal oxyhemoglobin concentration, which constitutes the driving force for the transport of oxyhemoglobin to the interstitial space. Interestingly, at a maximal effective concentration of bradykinin (100 nM), inhibition of coronary vasodilation by hemoglobin was less pronounced. Two factors may contribute to this effect: 1) The transport of proteins (MW about 60,000) across the coronary endothelium of the isolated perfused rat heart has been reported to be saturable. 46 For the present model, this indicates that, with increasing the arterial concentration of oxyhemoglobin, the ratio of the intraluminal to abluminal concentration rises. Consequently, the ratio of oxyhemoglobin to NO on the abluminal side of the endothelium following stimulation with 10-7 M bradykinin is diminished. 2) Alternatively, more NO may have passed directly from the endothelial cell via gap junctions to vascular smooth muscle without being scavenged by oxyhemoglobin. NO Release Induced by Acetylcholine, Serotonin, and ATP Acetylcholine has been shown to release EDRF from endothelial cells of large and resistance-sized vessels.1'58'59 Recent findings demonstrated that nitrogen oxides are released from the acetylcholinestimulated isolated rabbit heart. 13 In the present study, acetylcholine enhanced basal release of NO and cGMP, resulting in coronary vasodilation. The amounts of NO released by stimulation with acetylcholine were within the dose-response curve for exogenously applied NO (Figure 1 ). Furthermore, oxyhemoglobin decreased acetylcholine-induced changes in CPP and cGMP release. These findings strongly suggest that besides a possible role of adenosine,60 NO is an important mediator of the coronary vasodilation elicited by acetylcholine.
Serotonin exerts a dual effect on coronary arteries61,62: an endothelium-dependent vasodilation and a vasoconstriction by direct action on coronary vascular smooth muscle. Our finding that oxyhemoglobin reversed serotonin-induced vasodilation into a vasoconstriction is in accordance with this concept. In the present study, a low concentration of serotonin (10-8 M) was chosen to avoid coronary constriction. The underlying rationale was that because of the rapid uptake mechanism of arterial endothelial cells,63 the vascular smooth muscle was exposed to a much lower concentration of serotonin than the luminal side of the endothelium. Although measured increases in the release of NO and cGMP were rather small, the relation between the concentration of NO (2.3 nM) measured in the coronary effluent perfusate and the observed vasodilation (ACPP, -6%) was comparable to that elicited by the respective concentration of exogenously applied NO (Figure 1) . Again, this suggests that NO may play a role in the endothelium-dependent effects of serotonin on coronary resistance vessels. ATP is capable of activating P2 receptors on endothelial and vascular smooth muscle cells (for review, see Gordon64). Furthermore, in the intact coronary circulation of the isolated rat and guinea pig heart, ATP is rapidly degraded to adenosine by highly active ectonucleotidases. 65, 66 In the present study, ATP enhanced basal release of NO and cGMP (Table 4 ). This increase, however, was much less than with acetylcholine or bradykinin, although coronary vasodilation was maximal with all substances tested. Furthermore, the kinetics of the reversal of coronary vasodilation and NO release after cessation of ATP infusion were more rapid than those for acetylcholine and bradykinin. A possible explanation for these findings is that ATP is rapidly removed from the endothelial P2 receptor by being metabolized to adenosine and inosine. Comparing the degree of ATP-induced coronary vasodilation with the CPP changes that can be expected from the amount of NO measured in the coronary effluent, it is concluded that about one third of the ATP-induced relaxation may be mediated by NO. Although the ATP-induced vasodilation is caused by activation of vascular smooth muscle guanylate cyclase, adenosine, the degradative product of ATP, induces a pronounced stimulation of endothelial adenylate cyclase.67 This may have caused an additional part of the ATPinduced decrease of CPP.
Several criteria for chemical transmitters involved in the regulation of coronary blood flow have been established9: 1) The proposed transmitter is released under appropriate conditions; 2) exogenously applied transmitter should faithfully mimic physiological activation; 3) mechanisms of production and inactivation are present in the tissue in an appropriate location; 4) the activation of various inhibitors and blocking agents should have effects consistent with the hypothesis; and 5) quantitative studies should indicate that the amount and time course of transmitter released under physiological conditions is appropriate to give the indicated effect. Taking our findings together, the present study provides evidence that NO fulfills almost all of the above-mentioned criteria and thus is an important modulator of coronary vascular resistance. The challenging question of whether NO released under the respective conditions is derived from a single precursor (e.g., L-arginine) or whether other compounds (e.g., nitrosothiols) may be involved requires further investigation. Studies concerning the segmental localization of NO production (arterial versus capillary coronary endothelial cells) and the involvement of NO in the metabolic control of coronary blood flow are currently in progress in our laboratory. 1 
